The Global. Cinfa Biotech has announced that it will begin clinical studies in November 2015 for the development of its first biosimilar, B12019 (pegfilgrastim) in the oncology area. This announcement begins the journey of this company created in 2013, with an initial investment of 70 million euros, with headquarters in Spain and a subsidiary in Munich.